Counterweight Ventures LLC Acquires Shares of 6,250 Zimmer Biomet Holdings, Inc. $ZBH

Counterweight Ventures LLC bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 6,250 shares of the medical equipment provider’s stock, valued at approximately $565,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Inceptionr LLC bought a new stake in shares of Zimmer Biomet in the 3rd quarter worth approximately $1,217,000. PNC Financial Services Group Inc. increased its position in Zimmer Biomet by 9.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after buying an additional 13,883 shares in the last quarter. Wilsey Asset Management Inc. bought a new position in Zimmer Biomet during the 4th quarter valued at approximately $32,439,000. Dimensional Fund Advisors LP raised its stake in Zimmer Biomet by 1.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,269,122 shares of the medical equipment provider’s stock valued at $223,503,000 after buying an additional 39,146 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its stake in Zimmer Biomet by 257.2% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock valued at $3,091,000 after buying an additional 24,748 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ZBH shares. Wells Fargo & Company cut their target price on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. BTIG Research reaffirmed a “neutral” rating on shares of Zimmer Biomet in a research report on Monday, March 23rd. Canaccord Genuity Group set a $83.00 price target on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, April 7th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $102.70.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $87.50 on Friday. The business’s fifty day simple moving average is $86.09 and its two-hundred day simple moving average is $89.81. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The company has a market cap of $16.93 billion, a price-to-earnings ratio of 22.73, a P/E/G ratio of 2.58 and a beta of 0.46.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.23. The firm had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be given a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s payout ratio is 24.94%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.